Felsenstein Matthäus, Lindhammer Flora, Feist Mathilde, Hillebrandt Karl Herbert, Timmermann Lea, Benzing Christian, Globke Brigitta, Zocholl Dario, Hu Mengwen, Fehrenbach Uli, Sinn Bruno Valentin, Pelzer Uwe, Sauer Igor Maximillian, Pratschke Johann, Malinka Thomas
Department of Surgery, Campus Charité Mitte/Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Berlin Institute of Health (BIH), Charité-Universitätsmedizin Berlin, Anna-Louisa-Karsch-Str. 2, 10178 Berlin, Germany.
J Clin Med. 2022 Apr 23;11(9):2367. doi: 10.3390/jcm11092367.
(1) Background: Perineural invasion (PNI) is a common characteristic of pancreatic ductal adenocarcinoma (PDAC) and is present in most resection margins. We hypothesized that curative pancreatic tumor resection with long-term survival could only be achieved in PNI-negative patients. (2) Material and Methods: A retrospective investigation of PDAC patients who underwent curative-intended surgery during the period 2008 to 2019 was performed at our institution. (3) Results: We identified 571 of 660 (86.5%) resected patients with well-annotated reports and complete datasets. Of those, 531 patients (93%) exhibited tumors with perineural invasion (Pn1), while 40 (7%) were negative for PNI (Pn0). The majority of patients in the Pn1 group presented advanced tumor stage and positive lymph node infiltration. Patients in the Pn0 group showed an improved disease-free and long-term survival compared to the Pn1 group (p < 0.001). Subgroup analysis of all R0-resected patients indicated improved long-term survival and disease-free survival of R0 Pn0 patients when compared to R0 Pn1 patients (p < 0.001). (4) Conclusion: Our study confirmed that Pn0 improves the long-term survival of PDAC-resected cancer patients. Furthermore, PNI significantly challenges the long-term survival of formally curative (R0) resected patients. We provide new insights into the dynamics of PNI in pancreatic cancer patients which are needed to define subgroups of patients for risk stratification and multimodal treatment strategies.
(1) 背景:神经周围浸润(PNI)是胰腺导管腺癌(PDAC)的常见特征,且存在于大多数手术切缘中。我们假设只有在PNI阴性的患者中才能实现具有长期生存的根治性胰腺肿瘤切除术。(2) 材料与方法:在我们机构对2008年至2019年期间接受根治性手术的PDAC患者进行了回顾性研究。(3) 结果:我们从660例切除患者中确定了571例(86.5%)有详细注释报告和完整数据集的患者。其中,531例患者(93%)表现为神经周围浸润性肿瘤(Pn1),而40例(7%)PNI阴性(Pn0)。Pn1组的大多数患者呈现晚期肿瘤分期和阳性淋巴结浸润。与Pn1组相比,Pn0组患者的无病生存期和长期生存率有所改善(p < 0.001)。对所有R0切除患者的亚组分析表明,与R0 Pn1患者相比,R0 Pn0患者的长期生存率和无病生存率有所提高(p < 0.001)。(4) 结论:我们的研究证实,Pn0可提高PDAC切除术后癌症患者的长期生存率。此外,PNI对接受根治性(R0)切除患者的长期生存构成重大挑战。我们为胰腺癌患者PNI的动态变化提供了新的见解,这对于定义患者亚组以进行风险分层和多模式治疗策略是必要的。